Get started

PHARMA

$AMPE Ampio Pharmaceuticals Inc A Good Risk/Reward PlayWe are really liking the chart on $AMPE. You have the rounding bottom and there looks to be accumulation going on. Currently trading at $.62 a share, the 52-week low is $.35 a share. We believe $AMPE has breakout written all over it and there is an upcoming catalyst that can send the stock flying higher. The company is due to hear from the FDA shortly. Here's what the company said last month in its update: Ampio Pharmaceuticals has been in contact with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) following its re-submission of a revised protocol for AP-013, which the Company believes implements all of the Agency's recommendations provided since the beginning of the SPA review cycle. The Agency confirmed that it would make every effort to expedite this review, however due to a heavy workload, they were not able to commit to providing a response to the Company's SPA re-submission earlier than the 45-day window outlined in the Guidance for Industry Special Protocol Assessment, leading the Company to expect the response will be in mid-June rather than late May 2019, as previously predicted. There is some debate on social channels as to when this news will hit the tape. Some are saying any day now, while others are saying after the July 4th holiday. As always, trade with caution and use protective stops. Good luck to all!
ALong
by InsiderFinancial
G1 Therapeutics RALLYEarnings/News Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co Analyst Actions JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
GLong
by dorfmanmaster
GlaxoSmithKline - Top of the range, limited upside.SELL – GLAXOSMITHKLINE (GSK) GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. Fundamentals GlaxoSmithKline has shifted strategy in recent months by increasing spend on science research and development by 12%, this has been seen by some as too little to late. AstraZeneca implemented a similar plan 5 years ago. Revenues were flat at GSK in the most recent market update. The timing of the additional investment is also under scrutiny as net debt increased from £23.9bn to £28.7bn. The share price feels a bit heavy here and it could be time to cash in. Best Broker Target Price: 1750p (Jefferies 23/04/2019) Worst Broker Target Price: 1575p (Deutsche Bank 08/07/2019) Technical Analysis The share price of GlaxoSmithKline has been trading in a huge range since mid-2015. The price has gyrated between 1227-1745 for many months and there appears to have been another failure at the upper end of the range. The week commencing 29th July 2019 ended with a inverted hammer candle, this is a bearish signal and suggests further downside could be seen in the short term. It is possible that we could see a continuation of the range. Recommendation: Sell between 1600-1750p Stop: 1780p Target: 1230p
LSE:GSKShort
by Investamate
Adaptive Biotechnology (MSFT & Genentech partner)"Microsoft and Adaptive Biotechnologies announce partnership using AI to decode immune system; diagnose, treat disease" They also have a partnership with Genentech (January 2019) ADPT - Adaptive Biotechnology IPO: June 27th 2019 - open @$39 (above current price) Vision: We aim to improve people’s lives by translating the scale and precision of their adaptive immune systems into products to help diagnose, treat, and monitor disease. Great risk reward with an entry right now. If we break the IPO low @36.2, I would recommend exiting part of your position. Happy trading! dorfmanmaster P.S: I think this is a short-term, not to mention long-term good investment. I recommend looking for their research on cellular therapy.
NASDAQ:ADPTLong
by dorfmanmaster
ACASTI PHARMA INC - NASDAQ: $ACST Picking Its Head UpSince breaking-out last October'18, ACASTI PHARMA INC - NASDAQ:ACST has been trading in a side-ways grind with no real progress towards higher levels to speak of. However, we've been monitoring the action closely for some time now and it appears that ACST may just be starting to pick its head up as evidenced in the Daily chart above. With the stock trading above all of its important moving averages 20/50/200 DMA's, the technical picture remains favorable despite the lack of upside progress over the past 8-9 months. While ACST requires further work, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead. In particular, should ACST be capable of clearing the $1.15 hurdle, such development may just ignite the stock and finally break free from its long slumber. Thus, both investors/traders may want to put ACST front-and-center on their radars.
A
by InsiderFinancial
APELLIS PHARMACEUTICALS INC - NASDAQ: $APLS Knocking On DoorAfter breaking-out in early Spring (March), APELLIS PHARMACEUTICALS INC - NASDAQ:APLS has been building-out its right side in a prolonged base and presently finds itself nearing a potential move that may just catapult the stock into higher ground as evidenced in the Daily chart above. While further work is required, APLS presently trades above all of its important moving averages 20/50/200 DMA's, which depicts a healthy technical posture. Additionally, when one extends the time-frame out to the Weekly chart, we can also observe that APLS is presently knocking on the door to a potential move out of its long-drawn base. Thus, both investors/traders may want to pay close attention to the action in the days/weeks ahead for further clues/evidence that APLS may just be on the verge of breaking free from its base. Should APLS be capable of going topside of the $22.25 figure at any time in the days ahead, such development, should it occur, would like trigger its next meaningful advance into higher ground with and initial $24-$26 objective and perhaps higher.
NASDAQ:APLS
by InsiderFinancial
AMARIN CORP - NASDAQ: $AMRN Setting-UpAfter breaking to higher ground in 1Q19 and subsequently drifting back down to its original break-out level in the upper teen's, the shares of AMARIN CORP NASDAQ: AMRN are once again starting to show signs of potentially setting-up for another attempt at loftier levels as evidenced in the Daily chart above. While AMRN presently finds itself in drift mode working on its right-side, the stock continues to display favorable technical characteristics trading above all of its important moving averages (20/50/200 DMA's). Although further work is required, it appears that we may just witness a repeat of 1Q whereby buyers once again start to take control of the stock and should such scenario materialize, we suspect that it may have eyes for the $22 - $24 zone once again in the short-term. Thus, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for signs/clues that a move for greener pastures is underway.
NASDAQ:AMRN
by InsiderFinancial
Pieris Pharmaceuticals Inc. NASDAQ: PIRS Shaping-Up Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. The company's clinical pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia. TECHNICAL After breaking-out on large meaningful volume two weeks ago, shares of Pieris Pharmaceuticals Inc. - PIRS now finds itself digesting/consolidating the recent thrust into higher ground on lower volume and in a very constructive manner. When observing the Daily chart above, we can see that PIRS is coming out of a rounding bottom and has recaptured its 200 DMA on the recent move. In addition, we can also see that PIRS now finds itself trading above all of its important moving averages (20/50/200 DMA's), which depicts a favorable technical posture. Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we would not be surprised if a move into the $5- $6 zone were to occur in the not too distant future.
P
by InsiderFinancial